Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

417 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dissemination pattern of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue.
Ishii Y, Tomita N, Suzuki T, Ishiyama Y, Kishimoto K, Yamamoto E, Koyama S, Hattori Y, Nakajima Y, Motohashi K, Takasaki H, Kawasaki R, Hashimoto C, Takemura S, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y. Ishii Y, et al. Among authors: motohashi k. Leuk Lymphoma. 2015;56(9):2750-2. doi: 10.3109/10428194.2015.1010161. Epub 2015 Mar 6. Leuk Lymphoma. 2015. PMID: 25644745 No abstract available.
R-CHOP therapy alone for limited-stage follicular lymphoma.
Tomita N, Suzuki T, Ishiyama Y, Miyashita K, Takahashi H, Numata A, Ito S, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Yamazaki E, Taguchi J, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y. Tomita N, et al. Among authors: motohashi k. Leuk Res. 2015 Jun;39(6):582-5. doi: 10.1016/j.leukres.2015.03.008. Epub 2015 Apr 6. Leuk Res. 2015. PMID: 25866096 Clinical Trial.
The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.
Tomita N, Suzuki T, Miyashita K, Yamamoto W, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Taguchi J, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Kawamoto K, Sone H, Takizawa J. Tomita N, et al. Among authors: motohashi k. Leuk Lymphoma. 2016 Dec;57(12):2763-2770. doi: 10.1080/10428194.2016.1195498. Epub 2016 Jun 20. Leuk Lymphoma. 2016. PMID: 27320054
Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study.
Tachibana T, Andou T, Tanaka M, Ito S, Miyazaki T, Ishii Y, Ogusa E, Koharazawa H, Takahashi H, Motohashi K, Aoki J, Nakajima Y, Matsumoto K, Hagihara M, Hashimoto C, Taguchi J, Fujimaki K, Fujita H, Fujisawa S, Kanamori H, Nakajima H; Yokohama Cooperative Study Group for Hematology (YACHT). Tachibana T, et al. Among authors: motohashi k. Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):415-421. doi: 10.1016/j.clml.2018.03.009. Epub 2018 Mar 31. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29673622
Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma.
Koyama S, Fujisawa S, Watanabe R, Itabashi M, Ishibashi D, Ishii Y, Hattori Y, Nakajima Y, Motohashi K, Takasaki H, Kawasaki R, Hashimoto C, Yamazaki E, Koharazawa H, Takemura S, Tomita N, Sakai R, Motomura S, Nakajima H. Koyama S, et al. Among authors: motohashi k. Int J Lab Hematol. 2017 Feb;39(1):112-117. doi: 10.1111/ijlh.12592. Epub 2016 Nov 24. Int J Lab Hematol. 2017. PMID: 27885817 Clinical Trial.
Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
Watanabe R, Tomita N, Itabashi M, Ishibashi D, Yamamoto E, Koyama S, Miyashita K, Takahashi H, Nakajima Y, Hattori Y, Motohashi K, Takasaki H, Ohshima R, Hashimoto C, Yamazaki E, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y. Watanabe R, et al. Among authors: motohashi k. Eur J Haematol. 2014 Mar;92(3):204-10. doi: 10.1111/ejh.12221. Epub 2013 Nov 28. Eur J Haematol. 2014. PMID: 24283206
Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
Numata A, Kajiyama R, Itabashi M, Ishii Y, Yamamoto W, Motohashi K, Matsumoto K, Hagihara M, Ishigatsubo Y, Fujisawa S. Numata A, et al. Among authors: motohashi k. Leuk Lymphoma. 2016;57(1):201-2. doi: 10.3109/10428194.2015.1037763. Epub 2015 May 12. Leuk Lymphoma. 2016. PMID: 25860242 No abstract available.
417 results